- Home
- PECO vs TNGX Comparison
PECO vs TNGX Comparison
Compare PECO & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PECO | TNGX |
|---|---|---|
| Founded | 1991 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 4.5B |
| IPO Year | 2010 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PECO | TNGX |
|---|---|---|
| Price | $40.43 | $25.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $39.71 | $21.78 |
| AVG Volume (30 Days) | 850.0K | ★ 2.1M |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.26% | N/A |
| EPS Growth | ★ 74.51 | 26.89 |
| EPS | ★ 0.56 | N/A |
| Revenue | ★ $726,594,000.00 | $62,384,000.00 |
| Revenue This Year | $5.82 | N/A |
| Revenue Next Year | $3.81 | N/A |
| P/E Ratio | $71.68 | ★ N/A |
| Revenue Growth | 9.86 | ★ 48.29 |
| 52 Week Low | $32.98 | $6.25 |
| 52 Week High | $44.38 | $34.39 |
Technical Indicators
Market Signals| Indicator | PECO | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 36.82 | 42.01 |
| Support Level | $40.18 | $25.33 |
| Resistance Level | $42.54 | $25.76 |
| Average True Range (ATR) | 0.80 | 1.64 |
| MACD | -0.32 | -0.23 |
| Stochastic Oscillator | 22.05 | 7.32 |
Price Performance
Historical ComparisonAbout PECO Phillips Edison & Company Inc.
Phillips Edison & Co Inc is a real estate investment trust. The company also operates a third-party investment management business providing property management and advisory services to four unconsolidated institutional joint ventures, in which it has a partial ownership interest, and one private fund. It invests in well-occupied, grocery-anchored neighborhood and community shopping centers. It holds an integrated in-house operating platform built on a market of expertise designed to optimize property value and consistently deliver a great shopping experience.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.